Correspondence (reply): In Reply

Por Heinemann, Volker, Stintzing, Sebastian
Publicado em 2009

Standards and Challenges of Care for Colorectal Cancer Today

Por Werner, Jens, Heinemann, Volker
Publicado no Visc Med (2016)

Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer

Por Bauerfeind, Ingo, Elling, Dirk, Heinemann, Volker
Publicado em 2010

Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives

Por Holch, Julian, Stintzing, Sebastian, Heinemann, Volker
Publicado no Visc Med (2016)

Accomplishments in 2008 in the Treatment of Metastatic Pancreatic Cancer

Por Heinemann, Volker, Philip, Philip A., Pelzer, Uwe
Publicado em 2009

Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer

Por Harbeck, Nadia, Heinemann, Volker, Loibl, Sibylle, Untch, Michael
Publicado em 2008

Importance of performance status for treatment outcome in advanced pancreatic cancer

Por Boeck, Stefan, Hinke, Axel, Wilkowski, Ralf, Heinemann, Volker
Publicado em 2007

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Por Heinemann, Volker, Boeck, Stefan, Hinke, Axel, Labianca, Roberto, Louvet, Christophe
Publicado em 2008

The Treatment of Colorectal Carcinoma With Monoclonal Antibodies: The Importance of KRAS Mutation Analysis and EGFR Status

Por Stintzing, Sebastian, Heinemann, Volker, Jung, Andreas, Moosmann, Nicolas, Hiddemann, Wolfgang, Kirchner, Thomas
Publicado em 2009

Ductal Pancreatic Adenocarcinoma: Surgery, Pathology Work-up, and Neoadjuvant, Adjuvant, and Palliative Treatments

Por Seufferlein, Thomas, Porzner, Marc, Heinemann, Volker, Tannapfel, Andrea, Stuschke, Martin, Uhl, Waldemar
Publicado em 2014

Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts

Por Kruger, Stephan, Haas, Michael, Ormanns, Steffen, Bächmann, Sibylle, Siveke, Jens T, Kirchner, Thomas, Heinemann, Volker, Boeck, Stefan
Publicado em 2014

UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer

Por Schulz, Christoph, Heinemann, Volker, Schalhorn, Andreas, Moosmann, Nikolas, Zwingers, Thomas, Boeck, Stefan, Giessen, Clemens, Stemmler, Hans-Joachim
Publicado em 2009

Projections of cancer incidence and cancer‐related deaths in Germany by 2020 and 2030

Por Quante, Anne S., Ming, Chang, Rottmann, Miriam, Engel, Jutta, Boeck, Stefan, Heinemann, Volker, Westphalen, Christoph Benedikt, Strauch, Konstantin
Publicado no Cancer Med (2016)

A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer

Por Mihaljevic, Andre, Büchler, Peter, Harder, Jan, Hofheinz, Ralf, Gregor, Michael, Kanzler, Stephan, Schmiegel, Wolff, Heinemann, Volker, Endlicher, Esther, Klöppel, Günter, Seufferlein, Thomas, Geissler, Michael
Publicado em 2009

Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial

Por Niess, Hanno, von Einem, Jobst C, Thomas, Michael N, Michl, Marlies, Angele, Martin K, Huss, Ralf, Günther, Christine, Nelson, Peter J, Bruns, Christiane J, Heinemann, Volker
Publicado no BMC Cancer (2015)

The Reality in the Surveillance of Breast Cancer Survivors—Results of a Patient Survey

Por Stemmler Hans-Joachim, Lässig Dorit, Stieber Petra, Bauerfeind Ingo, Kahlert Steffen, Fasching Peter Alexander, Beckmann Matthias Wilhelm, Glattes Margrit, Goldmann-Posch Ursula, Hoffmann Verena, Untch Michael, Heinemann Volker
Publicado em 2008-01-01

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials

Por Ormanns, Steffen, Haas, Michael, Baechmann, Sibylle, Altendorf-Hofmann, Annelore, Remold, Anna, Quietzsch, Detlef, Clemens, Michael R, Bentz, Martin, Geissler, Michael, Lambertz, Helmut, Kruger, Stephan, Kirchner, Thomas, Heinemann, Volker, Boeck, Stefan
Publicado no Br J Cancer (2016)

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic co...

Por Teschendorf Christian, Sieber Markus, Denzlinger Claudio, Bangerter Markus, Mayerle Julia, Vehling-Kaiser Ursula, Kullmann Frank, Stintzing Sebastian, Hinke Axel, von Weikersthal Ludwig, Giessen Clemens, Freiberg-Richter Jens, Schulz Christoph, Modest Dominik, Moosmann Nicolas, Aubele Philipp, Heinemann Volker
Publicado em 2011-08-01

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic co...

Por Giessen, Clemens, von Weikersthal, Ludwig Fischer, Hinke, Axel, Stintzing, Sebastian, Kullmann, Frank, Vehling-Kaiser, Ursula, Mayerle, Julia, Bangerter, Markus, Denzlinger, Claudio, Sieber, Markus, Teschendorf, Christian, Freiberg-Richter, Jens, Schulz, Christoph, Modest, Dominik Paul, Moosmann, Nicolas, Aubele, Philipp, Heinemann, Volker
Publicado em 2011

Polymorphisms in genes involved in EGFR-turnover are predictive for cetuximab efficacy in colorectal cancer

Por Stintzing, Sebastian, Zhang, Wu, Heinemann, Volker, Neureiter, Daniel, Kemmerling, Ralf, Kirchner, Thomas, Jung, Andreas, Folwaczny, Matthias, Yang, Dongyun, Ning, Yan, Sebio, Ana, Stremitzer, Stefan, Sunakawa, Yu, Matsusaka, Satoshi, Yamauchi, Shinichi, Loupakis, Fotios, Cremolini, Chiara, Falcone, Alfredo, Lenz, Heinz-Josef
Publicado no Mol Cancer Ther (2015)